# Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

> **NCT06926192** · — · RECRUITING · sponsor: **Peking Union Medical College** · enrollment: 100 (estimated)

## Conditions studied

- Hidradenitis Suppurativa (HS)
- Hidradenitis Suppurativa (Acne Inversa)
- Secukinumab

## Interventions

- **COMBINATION_PRODUCT:** Surgery combined with secukinumab

## Key facts

- **NCT ID:** NCT06926192
- **Lead sponsor:** Peking Union Medical College
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-21
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926192, "Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06926192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*